LAB COMPLETES ENROLLMENT IN CANCER PAIN TREATMENT TRIAL

A A

Lab International has completed patient enrollment for the pivotal Phase IIa trial of its fentanyl Taifun.

The multicenter, randomized, double blind, placebo-controlled trial is investigating the efficacy and safety of fentanyl Taifun for the treatment of breakthrough cancer pain, monitoring response at different fentanyl doses. The trial enrolled a total of 122 cancer patients on maintenance opioid therapy for persistent pain.

Chronic pain associated with advanced cancer is commonly treated with strong opioid analgesics, such as fentanyl. "Breakthrough" pain episodes are sudden and intense flares of pain